{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:12:04Z","timestamp":1773227524994,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Psoriasis is a chronic skin condition, for which the approval of several biologics has made a dramatic impact. Despite their initial treatment effectiveness, the challenge lies in understanding the long-term responses, as they may diminish over time. Limitations of drug survival analysis warrant the application of additional outcomes to fully capture the performance of a biologic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To provide a broader perspective on the global landscape of biologic agents\u2019 persistence in positive clinical response by comparing innovative therapies over a 5-year period through a systematic review and network meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We comprehensively identified studies in PubMed, Embase, Scopus and ClinicalTrials.gov. We defined two outcomes: (i) \u2018persistence at optimal response\u2019 (POR) or \u2018clinical remission\u2019, and (ii) \u2018persistence at suboptimal response\u2019 (PSR) or \u2018low disease activity\u2019. Outcomes were measured as the proportions of patients with continuous exposure to a biologic who achieved \u2265 90% or 100% improvement in Psoriasis Area and Severity Index at the end of the predefined 5-year follow-up period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven publications, comprising 18 randomized controlled trials and 11 202 patients, met the inclusion criteria and were included in the network meta-analysis. In the ranking analysis, guselkumab exhibited the highest cumulative probability of POR (0.84), followed by ixekizumab (0.82) and risankizumab (0.76). Conversely, etanercept (0.42), brodalumab (0.36), apremilast (0.25) and placebo (0.026) showed the lowest cumulative probabilities of POR. For PSR, guselkumab (0.86), ixekizumab (0.75) and risankizumab (0.71) also ranked highest, while brodalumab (0.42), secukinumab (0.23), etanercept (0.19) and placebo (0.019) presented the lowest PSR probabilities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The highest rates of persistence with clear or almost clear skin can be expected with guselkumab, ixekizumab and risankizumab compared with other biologics. The proposed proxy definitions of long-term persistence (POR and PSR) are reliable measures of patients being successfully treated that warrant further exploration and validation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae131","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:56:05Z","timestamp":1713171365000},"page":"1148-1155","source":"Crossref","is-referenced-by-count":7,"title":["Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score"],"prefix":"10.1093","volume":"49","author":[{"given":"Husein","family":"Husein-ElAhmed","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Hospital de Baza , Granada ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biosanitaria , IBS Granada, Granada ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Husein-ElAhmed","sequence":"additional","affiliation":[{"name":"Huetor-Tajar Health Center , Andalusian Health Service, Granada ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2025060209322016000_llae131-B1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"2025060209322016000_llae131-B2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2025060209322016000_llae131-B3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/09546634.2013.826341","article-title":"Biologic fatigue in psoriasis","volume":"25","author":"Levin","year":"2014","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2025060209322016000_llae131-B4","doi-asserted-by":"crossref","first-page":"625755","DOI":"10.3389\/fmed.2020.625755","article-title":"Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis","volume":"7","author":"Mourad","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025060209322016000_llae131-B5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/bjd.12583","article-title":"The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials","volume":"169","author":"Langley","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025060209322016000_llae131-B6","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025060209322016000_llae131-B7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025060209322016000_llae131-B8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit\u2013risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025060209322016000_llae131-B9","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1080\/09546634.2021.1950600","article-title":"Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population","volume":"33","author":"Xu","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025060209322016000_llae131-B10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","article-title":"Long-term benefit\u2013risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025060209322016000_llae131-B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000534364","article-title":"A systematic review and Bayesian network meta-analysis of medical therapies for lichen planopilaris","volume":"240","author":"Husein-ElAhmed","year":"2024","journal-title":"Dermatology"},{"key":"2025060209322016000_llae131-B12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5\u2005years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025060209322016000_llae131-B13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025060209322016000_llae131-B14","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE\u00a01\u20133 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025060209322016000_llae131-B15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5\u2005years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025060209322016000_llae131-B16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5\u2005years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025060209322016000_llae131-B17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40257-019-00466-2","article-title":"Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5\u2005years in a long-term, open-label, phase II study","volume":"20","author":"Lebwohl","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2025060209322016000_llae131-B18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5\u2005years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025060209322016000_llae131-B19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025060209322016000_llae131-B20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5\u2005years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025060209322016000_llae131-B21","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025060209322016000_llae131-B22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/jdv.18167","article-title":"Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2","volume":"36","author":"Fernandez","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025060209322016000_llae131-B23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/03007995.2020.1776233","article-title":"The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments","volume":"36","author":"Sain","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2025060209322016000_llae131-B24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","article-title":"Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA","volume":"13","author":"Fitzgerald","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025060209322016000_llae131-B25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population","volume":"74","author":"Doshi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025060209322016000_llae131-B26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09546634.2011.607425","article-title":"Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities","volume":"24","author":"Chan","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"2025060209322016000_llae131-B27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ad.2016.09.001","article-title":"Drug survival analysis is not a good\u00a0method for assessing the safety or effectiveness of \u00adsystemic therapies in psoriasis","volume":"108","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"2025060209322016000_llae131-B28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025060209322016000_llae131-B29","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.3390\/ijms232112849","article-title":"Could targeted pharmacotherapies exert a \u2018disease modification effect\u2019 in patients with chronic plaque psoriasis?","volume":"23","author":"Bellinato","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025060209322016000_llae131-B30","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025060209322016000_llae131-B31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae131\/58244103\/llae131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1148\/59183655\/llae131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1148\/59183655\/llae131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:32:36Z","timestamp":1748871156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1148\/7645633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,15]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae131","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,15]]}}}